Physician profile
Agnes Ubani
NPI 1285702894
$8,293.11
in general payments reported to CMS, 2019-2025
41 companies · $937 in 2025
The $937 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,034 · 2020: $1,454 · 2021: $1,310 · 2022: $924 · 2023: $695 · 2024: $939 · 2025: $937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,570.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,742.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $974.21 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $906.77 | 2019-2025 | Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $638.86 | 2019-2025 | Farxiga |
| Pfizer INC. | $508.73 | 2019-2024 | |
| Lilly USA, LLC | $480.44 | 2019-2025 | Jardiance, Mounjaro |
| Novartis Pharmaceuticals Corporation | $346.09 | 2019-2023 | |
| Merz North America, INC. | $345.00 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $344.86 | 2019-2025 | |
| Allergan, INC. | $301.21 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.84 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $159.31 | 2019-2021 | |
| Abbott Laboratories | $151.87 | 2021-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $146.80 | 2019-2025 | Pifeltro, Capvaxive |
| Kowa Pharmaceuticals America, INC. | $137.81 | 2019-2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Agnes Ubani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.